Biosimilars

Brain Cancer

HER2+ Breast Cancer

Breast Cancer

CAR T-cell Therapy

COVID-19

Disparities in Cancer Care

Colorectal Cancer

Gastric Cancer

Hepatocellular Carcinoma

Pancreatic Cancer

Gastrointestinal Cancer

Prostate Cancer

Urothelial Cancer

Genitourinary Cancers

Global Oncology

Ovarian Cancer

Gynecologic Oncology

Head & Neck Cancers

Chronic Lymphocytic Leukemia

Mantle Cell Lymphoma

Multiple Myeloma

Myeloproliferative Neoplasms

Non-Hodgkin Lymphoma

Hematologic Oncology

Immuno-Oncology

Lung Cancer

Melanoma & Skin Cancer

Oncology Business Management

Pediatric Oncology

Precision Medicine in Oncology®

Sarcomas

Supportive Care

Preclinical cytotoxicity was demonstrated with anti-CD38-CAR-gamma-delta T cells in multiple myeloma.

Anti-CD38-CAR-γδ T Cells Show Preclinical Cytotoxicity in Myeloma

MT-8421, a novel engineered toxin body targeting CTLA-4, was not associated with grade 4 or 5 toxicities in patients with select advanced solid tumors.

MT-8421 Displays Acceptable Safety Profile in First-in-Human Trial for Advanced Solid Tumors

SAR444200-mediated targeting of GPC3-expressing solid tumors was safe and showed early signs of antitumor activity in a phase 1/2 study. 

SAR444200 Demonstrates Safety, Signals of Clinical Activity in Advanced GPC3+ HCC, Other Solid Tumors

The feasibility and safety of treatment with SAR443216 support the further investigation of this agent in patients with advanced HER2-positive tumors.

SAR443216 Engages HER2 With Manageable Toxicity in Advanced HER2+ Solid Tumors

News

OncClub

All Oncology News

Media

Insights

MedNews Week

OncChats

OncLive News Network®

OncLive TV

Peer Exchange

Podcasts

Rapid Readouts

Conferences

Conference Coverage

Conference Listing

Events

Giants of Cancer Care

CME/CE

Scientific Interchanges

State of the Science Summit / IPC

National Fellows Forum

Webinars

Partners

Publications

Resources

Consensus Viewpoints

Interactive Tools

Biomarker Consortium

Subscribe

 team as an assistant editor in 2025 after previously working on the 

Articles

 in November 2021 as a senior editor and became the website's managing editor in October 2023. Before arriving at MJH Life Sciences, he spent nearly a decade covering professional and high school sports—including the New Jersey Devils and the NHL from 2016 to 2021—for The Star-Ledger and NJ.com. Email: chryan@onclive.com

Patients with relapsed/refractory MCL who opted for elective treatment interruptions from venetoclax/ibrutinib experienced durable responses. 

7-Year Data Show Feasibility of Elective Treatment Interruption of Venetoclax/Ibrutinib in R/R MCL 

Kyle Doherty joined MJH Life Sciences in 2021 and is the lead editor for 

as well as news and conference updates for OncLive.com. Email: kdoherty@mjhlifesciences.com

Caroline Seymour is your initial point of contact for the 

™. She joined the company in 2018 as an assistant editor, with expertise in video production and print/digital publication. Email: cseymour@onclive.com​ 

Retifanlimab demonstrated durable activity with a tolerable safety profile in patients with chemotherapy-naive MCC.

Retifanlimab Adds FDA-Approved Option to Merkel Cell Carcinoma Treatment Landscape

 as an assistant editor in October 2022. Leveraging an educational background in the life sciences and prior experience conducting interviews in a university setting, she plays a key role in shaping social media strategy, covering live conferences, and producing multimedia content for both print and digital platforms. Email: 

Megan Melody, MD, discusses how embracing authenticity, building patient trust, and supporting fellow female oncologists are key to thriving in the field.

Embracing Authenticity and Fostering Community Are Essential for Empowering Women in Oncology

A discovery by researchers from Mayo Clinic may help explain why immunotherapy hasn't been helpful for many patients with metastatic colorectal cancer.

Mayo Clinic Researchers Identify Proteins Linked to Immunotherapy Resistance in Metastatic Colorectal Cancer

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

Advertise

About OncLive

Editorial Board

MJH Life Sciences brands

Contact Us

Privacy

Terms & Conditions

Do Not Sell My Information

OncLive - Clinical Oncology News, Cancer Expert Insights

Facebook

LinkedIn

Youtube

Spotlight

In-person and virtual events just for HCPs

CME Opportunities

Specialty

1rem

primary

View

A National Perspective on the Multidisciplinary Management of Breast Cancer Through the COVID-19 Pandemic

Videos

This OncLive® webinar will focus on the impact of COVID-19 in patients with breast cancer and the innovative ways in which treatment has evolved during this time. We will feature a panel of experts from the nation’s leading cancer centers, led by Eric P. Winer, MD, to discuss important topics and key information for treating patients with breast cancer.

Regional differences in the management of patients with breast cancer during the COVID-19 pandemic

Institutional best practices for treating patients with breast cancer that have the novel coronavirus or who may be at risk for developing it

Guidelines on the prioritization and management of patients with breast cancer

Professor, Medicine, Harvard Medical School

Director, Breast Oncology Center, Dana-Farber Cancer Institute

Physician Active Staff, Medicine, Brigham And Women's Hospital

Thompson Chair, Breast Cancer Research, Dana-Farber Cancer Institute

Richardson and Marilyn Jacobs Preyer Distinguished Professor for Breast Cancer Research

Chief of the Division of Oncology, Stanford University Medical Center

Chief, Breast Service, Department of Surgery

Anne Burnett Windfohr Chair of Clinical Oncology

Professor of Surgery, Weill Cornell Medical College

 : Novartis / In association with Dana Farber

A National Perspective on the Multidisciplinary Management of Breast Cancer Through the COVID-19 Pandemic

Newsletter

Latest Conference Coverage